Innate Pharma (IPH) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Leadership and Strategic Direction

• New CEO with extensive oncology and commercial experience aims to advance assets further in-house and eventually build a commercial organization.

• Leadership team includes experienced executives in scientific, clinical, and U.S. operations roles.

• Strategic focus refined to three pillars: ANKET platform, antibody-drug conjugates (ADCs), and late-stage assets including Lacutamab and Monalizumab.

• Highlighted expertise in innate immunity and antibody engineering, advancing a diverse pipeline of proprietary and partnered cancer therapies.

• Outlined a solid strategy for long-term growth, with seven key clinical programs and a cash position of €96.4m as of September 30, 2024.

Pipeline and Clinical Progress

• Seven clinical assets with an eighth entering the clinic soon, spanning proprietary and partnered programs.

• ANKET platform enables rapid development of multi-specific NK cell engagers, with IPH6501 in Phase 1/2 for B-cell NHL and partnership with IFLI for follicular lymphoma.

• ADC portfolio led by IPH4502, targeting Nectin-4, entering Phase 1 in January 2025, with efficacy in low/moderate expressing tumors and Padcev-resistant populations.

• Late-stage assets include lacutamab (anti-KIR3DL2) with accelerated approval pathway and monalizumab (partnered with AstraZeneca) in Phase 3 PACIFIC-9 trial for NSCLC.

• Robust publication record in high-impact journals, underscoring scientific leadership in NK cell therapies and immune cell engagers.

Key Clinical and Regulatory Milestones

• Lacutamab received FDA Fast Track and EMA PRIME designations, with positive Phase 2 data in Sézary syndrome and mycosis fungoides; Phase 3 to start with expanded patient eligibility.

• FDA endorsed accelerated approval path for lacutamab, agreed on dose, and removed need for companion diagnostic in mycosis fungoides.

• IPH4502 demonstrated preclinical efficacy in high, moderate, and low Nectin-4 expressing tumors, including activity in Padcev-resistant models.

• Sanofi partnership validates ANKET platform, with CD123 asset showing durable responses and favorable safety in AML.

• Multiple mid-term clinical milestones expected from 2025 to 2027, including expansion studies, dose optimization, and potential accelerated approvals.